Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lamotrigine 25mg; lamotrigine 25mg - chewable/dispersible tablet - 25 mg - active: lamotrigine 25mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium active: lamotrigine 25mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium - epilepsy adults (over 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome. bipolar disorder (adults 18 years of age and over) arrow - lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lamotrigine 2mg - chewable/dispersible tablet - 2 mg - active: lamotrigine 2mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium - epilepsy adults (over 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome. bipolar disorder (adults 18 years of age and over) arrow - lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lamotrigine 50mg; lamotrigine 50mg - chewable/dispersible tablet - 50 mg - active: lamotrigine 50mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium active: lamotrigine 50mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium - epilepsy adults (over 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome. bipolar disorder (adults 18 years of age and over) arrow - lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lamotrigine 5mg; lamotrigine 5mg - chewable/dispersible tablet - 5 mg - active: lamotrigine 5mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium active: lamotrigine 5mg excipient: colloidal silicon dioxide as silica - colloidal anhydrous croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose povidone purified talc purified water ribes nigrum saccharin sodium - epilepsy adults (over 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with lennox-gastaut syndrome. children (2 to 12 years of age) arrow - lamotrigine is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with lennox-gaustaut syndrome. bipolar disorder (adults 18 years of age and over) arrow - lamotrigine is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bendroflumethiazide 2.5mg;  ;   - tablet - 2.5 mg - active: bendroflumethiazide 2.5mg     excipient: lactose purified talc starch stearic acid - bendrofluazide is indicated in the treatment of oedema associated with conditions such as: congestive heart failure, nephrotic syndrome and cirrhosis of the liver.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bendroflumethiazide 5mg;  ;   - tablet - 5 mg - active: bendroflumethiazide 5mg     excipient: lactose purified talc starch stearic acid - bendrofluazide is indicated in the treatment of oedema associated with conditions such as: congestive heart failure, nephrotic syndrome and cirrhosis of the liver.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate mannitol pregelatinised maize starch starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 21.78mg equivalent to 20 mg lisinopril;   - tablet - 20 mg - active: lisinopril dihydrate 21.78mg equivalent to 20 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide pregelatinised maize starch magnesium stearate mannitol starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 5.445mg equivalent to 5.0 mg lisinopril;   - tablet - 5 mg - active: lisinopril dihydrate 5.445mg equivalent to 5.0 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide pregelatinised maize starch magnesium stearate mannitol starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - norfloxacin 400mg;   - film coated tablet - 400 mg - active: norfloxacin 400mg   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white oy-b-28920 amb purified water - upper and lower, complicated and uncomplicated acute urinary tract infections including cystitis, pyelitis, cystopyelitis, pyelonephritis, chronic prostatitis, epididymitis, and those urinary infections associated with urologic surgery, neurogenic bladder or nephrolithiasis caused by bacteria susceptible to norfloxacin;